The pharmacokinetic and thrombolytic properties were determined of two recombinant single-chain chimeric plasminogen activators (PA) consisting of u-PA-33k. a lowmolecular weight derivative of single-chain urokinase-type PA (scu-PA) comprising amino acids Ala'32 through Leu4", and of either a single-chain variable region fragment (Fv) derived from the fibrin fragment D-dimer-specific monoclonal antibody M A -I 5C5 (K12GOS32) or of the deglycosylated single-chain Fv fragment obtained by substitution of Am8* with Glu (K12G2SJ2). Following bolus injection in hamsters, clearances of recombinant scu-PA (rscu-PA) and of K12GOS32 were similar. In contrast, clearance of K12G2S32 was fourfold slower than that of rscu-PA. The thrombolytic potency (percent lysis per U-PA administered in milligrams per kilogram body weight) and specific thrombolytic activity (percent lysis per microgram per milliliter steady-state plasma U-PA antigen level) of these compounds were studied in hamsters with an experimental pulmonary embolus consisting of a human plasma clot injected via the jugular vein. The doses of K12GOS32 and K12G2S32 required to obtain HE BLOOD fibrinolytic system comprises an inactive T proenzyme, plasminogen, that can be converted to the active enzyme, plasmin, that degrades fibrin into soluble fibrin degradation products. Two immunologically distinct physiological plasminogen activators (PA) have been identified: the tissue-type PA (t-PA) and the urokinase-type PA (u-PA). Inhibition of the fibrinolytic system may occur either at the level of the PA, by specific plasminogen activator inhibitors, or at the level of plasmin, mainly by a,-antiplasmin. ' In contrast to t-PA, single-chain u-PA (scu-PA) does not bind to fibrin, possibly limiting its thrombolytic potential. Targeting of scu-PA to a thrombus by combining the antigenbinding properties of a fibrin-specific antibody with its catalytic domain in a single molecule, has resulted in a significant increase of both its in vitro fibrinolytic and its in vivo thrombolytic p~t e n c i e s .~.~ Targeting has been achieved by chemical conjugation of scu-PA and a monoclonal antibody directed against the NH2-terminal region of the fi-chain of fibrin, 59D8: or a monoclonal antibody specific for fragment Ddimer of cross-linked human fibrin (MA-1 5C5).5-8 A recombinant chimeric PA, rscu-PA-32kf59D8, in which intact 59D8
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maximal rate of clot lysis were sixfold and 1 1 -fold lower than that of rscu-PA. The steady-state u-PA-related plasma antigen levels of K12GOS32 and K12G2S32 required to obtain maximal rate of clot lysis were 1 0-fold and fourfold lower than that of rscu-PA. Thus, targeting of K12GOS32 to the clot surface by means of its glycosylated Fv fragment results in a IO-fold increase of its specific thrombolytic activity and sixfold increase of its thrombolytic potency as compared with those of rscu-PA. Targeting of K12G2S32 to the clot surface by means of its deglycosylated Fv fragment results in only a twofold increase of its thrombolytic activity. However, its fourfold slower clearance, combined with its twofold higher specific thrombolytic activity, results in an 1 1 -fold increase of its thrombolytic potency over that of rscu-PA. These findings indicate that the thrombolytic potency of chimeric antibody-targeted PA may be increased by increasing the specific thrombolytic activity, reducing the clearance, or both.
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was fused to scu-PA-32k (a low Mr, truncated scu-PA), yielded a 20-fold higher thrombolytic potency than scu-PA in a rabbit jugular vein thrombosis model.' A recombinant chimeric PA, rscu-PA-32kfMA-15C5, composed of a scu-PA-32k and intact, humanized MA-15C5 (MA-I5C5Hu), yielded an 1 Ifold higher thrombolytic potency than scu-PA in the same model." Recently, we have produced a single-chain variable region antigen-binding fragment (scFv) derived from MA-15C5, scFv-KI2Go, that bound to fragment D-dimer of human crosslinked fibrin with an affinity similar to that of intact MA-15C5." The scFv-K12Go fragment was linked to rscu-PA33k, yielding a single-chain chimeric PA KIZGOS32, with a 13-fold higher in vitro fibrinolytic potency than rscu-PA32k. 12 In the present study, we determined the comparative in vivo pharmacokinetic and thrombolytic properties of rscu-PA, of K12GOS3,, and of KIZG2S3,, a variant without Asnbased glycosylation of the scFv moiety, in hamsters.
MATERIALS AND METHODS

Proteins and Reagents
Murine monoclonal antibody MA-I5C5, which reacts specifically with fragment D-dimer of human cross-linked fibrin, was produced and characterized as described elsewhere.',' Human plasminogen, plasmin, fibrinogen, and fibrin fragment D-dimer were obtained and characterized as previously de~cribed.'~ Saruplase, a preparation of recombinant scu-PA (mu-PA) obtained by expression of cDNA encoding human xu-PA in Escherichia coli, was a gift from Griinenthal AG (Aachen, Germany 
Oligonucleotide-Directed Mutagenesis and DNA Sequencing
All DNA manipulations were performed essentially as described by Maniatis et a1.I4 Oligonucleotide-directed mutagenesis was performed by the gapped-duplex method of Kramer et all5 using the pMa/c vector system of Stanssens et a1.I6 This system uses phasmid (ie, phage/plasmid hybrid) vectors allowing cloning, site-directed mutagenesis, as well as sequencing to be performed with the same vector without recloning. Oligonucleotides were synthesized by the phosphoramidite method'' on an Applied Biosystems (Foster City, CA) 380A DNA synthesizer and purified by polyacrylamide gel electrophoresis as described." DNA sequencing was performed on singlestranded or double-stranded DNA by the dideoxynucleotide termination method of Sanger et all9 using the USB (Cleveland, OH) sequence kit, according to the manufacturer's manual.
Construction of cDNAs
pVLK,2GoS32 encoding K12GOS32 for expression in St9 cells was constructed as described previously." K,zGoS3z comprises the scFv-KI2GO sequence consisting of the Asp'-Arg'08 light chain-variable domain of MA-I5C5 linked with the Ala-Gly-Gln-Gly-Ser-Ser-Val synthetic linker to the Gln'-Ser114 heavy chain-variable domain that has been fused to the Ala132-Le~4ii-Asp156-Phe157 sequence of u-PA33k. In K1zGOS32, the thrombin cleavage site was removed by substitution of Phels7 with AspIs7. Site-directed mutagenesis in the pMa/c-12GoS3z plasmid for expression of scFv-Ki2Go, using the 27-mer deoxyoligonucleotide dATGGCTGGTGTCTTGAGCTTGC-AGACTG, exchanged the Asn-linked glycosylation site at the AAT codon for Asns8 in the V,-derived region of scFv-K12Go with CAA encoding Glu, yielding pMa/c-12G2S32. The 132 1 bp BumHI-XbaI restriction fragment of was then replaced by the corresponding BumHI-XbaI fragments from pMa/c-1 2G2S32, yielding P V L K~~G~S~~, encoding KIzG2S32. In addition, in KlzG2S3z, the TI"I codon for the PhelS7 was mutated in a GCT codon for Ala, resulting in the removal of the A~n "~-P h e '~~ thrombin cleavage site. The transfer vector pVLscu-PA encoding scu-PA for expression in Sf9 insect cells was constructed starting from the plasmid pULscu-PA: ' by partial Hind111 digestion, filling-in with Klenow fragment and religation, which created a NheI site at the 5' end of the cDNA 
Isolation of rscu-PA and Chimeric PA From Infected Sf 9 Insect Cells
The Sf9 cells were grown essentially as described by Summers and Smith." Recombinant baculovirus was produced and purified as described previouslyzz and the punty of the isolated recombinant virus was confirmed in filter-hybridization experiment^.'^ For the largescale production of the different proteins, 40 X lo6 Sf9 cells in 175-cm2 culture flasks were infected with 200 X lo6 plaque forming units of recombinant virus. After incubation for 48 hours at 27"C, the For personal use only. on October 25, 2017. by guest www.bloodjournal.org From conditioned medium was removed and centrifuged at 1,OOOg for removal of cell debris.
Chimeric PA were purified by ion exchange chromatography on SP-Sephadex followed by gel filtration on Sephadex-G 100 superfine, as described previously." rscu-PA was purified by affinity chromatography as described previously.2o
Analytical Techniques
Culture supernatants and purified proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% to 25% gradient gels according to the method of LaemmLZ4
Western blot analysis of the proteins separated by SDS-PAGE was performed essentially as de~cribed.'~ The transferred proteins were visualized with rabbit anti-MA-I 5C5 or anti-scu-PA antiserum in the first step, affinity purified goat anti-rabbit IgC antiserum conjugated to HRP in the second step, and the HRP substrate, 4-chloro-I-naphtol (BioRad).
Aminoterminal amino acid sequence analysis was performed using automated Edman degradation26 on an Applied Biosystems 470A gas-phase sequenator, and identification of amino acids by high-pressure liquid ~hromatography.'~ The concentrations of the different chimeric PA were determined initially by amino acid analysis performed in a Beckman (Palo Alto, CA) I 19CL amino acid analyzer after hydrolysis in 6 mol/L HCI in sealed ampules at 1IO"C for 20 hours, and subsequently with the Bradford protein assay2' (BioRad), which was calibrated against a secondary albumin standard (conversion factor, 1 .O f 0. I ; mean f S D n = 4). The concentration of purified MA-15C5 was determined with the Bradford protein assay calibrated with bovine y-globulin. The concentrations of u-PA-related antigen in rscu-PA, recombinant two-chain u-PA (rtcu-PA), and chimeric PA preparations were determined by enzyme-linked immunosorbent assay (ELISA) as previously described.29 D-dimer-binding protein was quantitated in ELISA as previously de~cribed.~ To confirm the integrity of the chimeric PA, their concentrations were also measured in a combined ELISA in which the proteins were bound to immobilized affinity purified rabbit-(anti-MA-I5C5)-IgG, whereafter the bound proteins were detected with a monoclonal antibody specific for rscu-PA (MA-4D 1 E8)29 conjugated to peroxidase and a peroxidase substrate.
The association constants of the chimeric PA for immobilized human fibrin fragment D-dimer, K,, were calculated from a plot of the ratio between bound immunoglobulin (as derived from the absorbance measured at 280 nm) and total immunoglobulin versus the amount of bound immunoglobulin.M Specific fibrinolytic activities were measured on bovine fibrin plates3' by comparison with the International Reference Preparation for Urokinase.
Purified rscu-PA or chimeric PA (final concentration, 1 pmol/L) were incubated with plasmin (0% to 7.5% molar ratio) in 0.05 mol/ L Tris-HCI buffer, pH 7.4, containing 0.038 mol/L NaCl and 0.01% Tween 80 (TNT buffer) at 37°C. At timed intervals (0 to 30 minutes), aliquots were removed and generated urokinase activity was measured with S-2444 (final concentration, 0.3 mmol/L) after 50-fold dilution. The conversion of one-chain to two-chain u-PA was monitored by SDS-PAGE on 10% to 15% gradient gels after reduction with dithioerythritol. Two-chain u-PA moieties were isolated by chromatography on benzamidine-Sepharose as described previously." Plasminogen activation was monitored by incubation of plasminogen (final concentration, 5 to 67 Fmol/L) at 37°C in 0. I mol/L phosphate buffer, pH 7.4, with rtcu-PA or the respective two-chain chimeric PA (final concentration, 1.8 or 0.8 nmol/L). Generated plasmin was measured at different time intervals (0 to 5 minutes) with S-225 1 (final concentration, I mmol/L) after 25-fold dilution of samples. Initial activation rates were obtained from plots of the concentration of generated plasmin versus time, and kinetic parameters (K, and k2) were determined from Lineweaver-Burk plots by linear regression analysis.
['251]Fibrin-Labeled Human Plasma Clot Lysis
Lysis of 1251-labeled human plasma clots (volume, 60 pL), immersed in 0.5 mL human citrated plasma, after addition of single-chain or two-chain u-PA-related protein, was monitored over 2 hours as described el~ewhere.~' The effect of the addition to plasma of purified fibrin fragment D-dimer (final concentration, 0 to 330 nmol/L) on the fibrinolytic activity of single-chain or two-chain chimeric PA or of u-PA (final concentration, 1 pg/mL) was determined in a similar manner.
Pharmacokinetics
The pharmacokinetic properties of rscu-PA, K12GoS32, and K ,~G z S~~ were determined in anesthetized hamstem by measurements of the residual plasma u-PA levels after bolus injection of 100 pg/ kg. Blood samples were taken at times 0. 
Lysis of ['2sI]Fibrin-Labeled Human Plasma Clots in a Hamster Pulmonary Embolism Model
The thrombolytic potencies of rscu-PA, K12GoS32, and KI2GzSS2 were determined in hamsters with an experimental pulmonary embolus consisting of a human plasma clot injected via the jugular vein, as described previ~usly.'~ Thrombolytic agents were infused intravenously over 60 minutes and lysis was measured 30 minutes after the end of the infusion as the difference between the radioactivity initially incorporated in the clot and the residual radioactivity in the lungs and heart. Blood samples were collected before the start of the infusion and at 90 minutes (for determination of residual fibrinogen and az-antiplasmin levels), and at 60 minutes (for determination of u-PA-related antigen) as described above.
Analysis of the Thrombolysis Data
The relative thrombolytic potency and specific thrombolytic activity of the compounds in hamsters and rabbits were determined by fitting the individual dose-response data (percent lysis versus dose in milligrams per kilogram, or percent lysis versus steady-state u-PArelated antigen in micrograms per milliliter) with an exponentially transformed sigmoidal function y = IOOc/( 1 + using the statistical program GraFit (Erithacus, Middlesex, UK). The mean f SEM of the parameters c (maximal lysis in percent), b (dose in mg/ kg or in pg/mL plasma antigen at which the rate of lysis is maximal), and z = (ac/4). eb (maximal rate of lysis, expressed as percent lysis per mg/kg compound infused or as percent lysis per pg/mL plasma antigen) were determined.35 The significance of the differences between these parameters was determined using Student's t-test.
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parent molecular weight of 54,000 for mu-PA and 57,000 for both K12G~S32 and K12G2S32. All proteins were obtained primarily as single-chain form, as evidenced by SDS-PAGE after reduction with dithioerythritol (Fig 2) . The equilibrium association constants for K12G0S32 and K12G& for immobilized fragment D-dimer were 0.5 x 1Olo mol/L-' and 1.6 k 10" mol/L-l, respectively, as compared
The amidolytic activity of all preparations of mu-PA, K12G0S32, and K12G2S32 was less than 5,000 IU/mg u-PArelated antigen before treatment and less than 1,000 IU/mg u-PA-related antigen after treatment with benzamidineSepharose, confirming that these proteins were secreted primanly as single-chain inactive forms. Plasmin caused a time- The specific fibrinolytic activities, measured on fibrin plates, of single-chain KI2G0S32, K12G2S32, and ~u -P A were similar ( Table 1 ). The specific fibrinolytic activities of twochain K~~G~s~~ and K~~G~s~~ were twofold lower than that 
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and of the chimeric PA (Table ) .
Of rtcu-PA.
RESULTS
Functional Characterization
Treatment with plasmin. Plasminogen activation by the two-chain derivatives of all chimeras followed MichaelisMenten kinetics, as evidenced by double reciprocal plots of the initial activation rate versus the plasminogen concentration (not shown). The catalytic efficiencies, derived from K, and k2 values obtained by linear regression analysis, are summarized in Table 1 .
IZ5ISfibrin clot lysis in plasma. K12G$32, K12G2S32, and mu-PA caused a time-and concentration-dependent lysis of a [1251]fibrin-labeled human plasma clot submerged in normal human plasma. The concentrations of the single-chain chimeric PA that were required to obtain 50% clot lysis in 2 hours (C,) were twofold lower than that of mu-PA ( Table  2 ). The Cs0 values for the two-chain derivatives obtained by cleavage of the single-chain forms with plasmin (at a 7.5% molar ratio), were twofold lower than those for their single-
Construction and Expression of rscu-PA, KIzGoS~Z. and KIZGZSX
The construction of the transfection vector pVLK12GoSs2 for expression of KIzGoSS2 has been described in detail elsewhere.12 In P V L K~~G~S~~, the expression vector of K12G2S32r the Asn-linked glycosylation site in the scFv moiety was removed by substitution of Amss with Glu. In addition, the PheI5' residue was replaced with Ala to eliminate the thrombin cleavage site in the u-PA moiety. The pVLscu-PA transfection vector for expression of mu-PA was constructed starting from pULscu-PA as described in Materials and Methods.
The structures of pVLK12GOS32,12 P V L K~~G~S~~, and pVLscu-PA were confirmed by cDNA sequencing (results not shown). The structure ofthese molecules is schematically represented in Fig 1. chain counterparts (Table 2 ).
Biochemical Characterization of Purified rscu-PA, K I z G o S~~. and KlZGZS3Z
SDS-PAGE of purified mu-PA, KI2GoS32, and K12G2S32 showed homogeneous preparations migrating with an a p
Pharmacokinetics in Hamsters and Rabbits
When mu-PA or the chimeric PA were injected as a bolus (100 pglkg) in groups of three to six hamsters, the plasma The concentration expressed in nmol/L is the total protein concentration as determined by Bradford assay. Data represent the mean f SEM of the number of experiments indicated in parentheses.
Abbreviation: Cs0, concentration required to obtain 50% lysis within 2 hours of a human plasma clot submerged in human plasma.
concentration increased to 1.1 +-0.06 pg/mL (mean f SEM) for rscu-PA, 1.2 f 0.12 pg/mL for KlzGoS32, and 2.2 f 0.2 pg/mL for K12G2S32. For both chimeric PA, more than 95% of the u-PA-related antigen that was detected in the ELISA for u-PA was also detected in the ELISA based on an IgGspecific catch antibody and a u-PA-specific tag antibody. This indicates that study proteins circulate primarily as intact chimeric molecules. The disappearance rate of all activators could be described by a sum of two exponential terms by graphical curve peeling. This yielded coefficients and exponents and calculated pharmacokinetic parameters as summarized in Table 3 . The plasma clearances were 2.5 ? 0.06 mL -min-' for rscu-PA, 3.1 f 0.05 mL min-' for K12GOS32, and 0.67 f 0.14 mL -min-' for K12G2S32.
When the chimeric PA were injected as a bolus (20 pg/kg) in two rabbits each, the plasma concentration increased to 0.48 k 0.02 pg/mL (mean f SD, n = 2) for K I~G , S~~ and 0.5 1 f 0.04 for K12G2S32. The disappearance rate of the activators in rabbits could be described by a sum of two exponential terms by graphical curve peeling. This yielded coefficients and exponents and calculated pharmacokinetic parameters as summarized in Table 3 . The plasma clearances were 26 2 4 mL-min-l for K12GOS32 and 2.9 f 0.04 mL -min-' for KI2G2!&, as compared with 30 mL -min-' for ~scu-PA.~
Thrombolytic Properties in a Hamster Pulmonary Embolism Model
The thrombolytic potencies of rscu-PA, K12GOS32, and KIZG2S32 were determined in a hamster pulmonary embolism model in which the pulmonary clot was prepared from normal human plasma. Dose-response data are summarized in Table 4 . Thirteen experiments with saline infusion yielded a value for spontaneous lysis at 90 minutes of 19% & 2% (mean f SEM). Fibrinogen levels and a2-antiplasmin levels were not different from the baseline values. With rscu-PA at doses ranging from 0.25 to 2.0 mg/kg, lysis increased from 30% 4 4% to 68% f 4%. The dose of rscu-PA at which the human plasma clots were lysed for 50% (ED,,) was 1 mg/kg. Fibrinogen levels were 8 1 % +-2% at the highest dose of rscu-PA, whereas the qantiplasmin levels at this dose were 54% +-7% of the baseline values. With K12GOS32 at doses ranging from 0.08 to 0.64 mg/kg, lysis increased from 22% f 1% to 71% f 3%. The value of ED5, was 0.23 mg/kg. Fibrinogen and a2-antiplasmin levels remained unchanged. With KI2G2S32 at doses ranging from 0.025 to 0.20 mg/kg, lysis increased from 20% k 3% to 64% f 5%. The value of ED5, was 0.10 mg/kg. Fibrinogen levels and a2-antiplasmin levels were not significantly different from baseline values.
The dose-response data (% lysis v mg/kg u-PA-related antigen administered) were fitted with the exponentially transformed sigmoidal function as described in the Methods (Fig  3A) , yielding values for c (maximal lysis achieved, expressed in %), z (maximal rate of lysis, expressed in % lysis per mg/ kg administered), and b (dose in mg/kg at which maximal rate of lysis occurs) as summarized in Table 5 . Maximal rates of lysis with rscu-PA, K12GOS3*, and KI2G& were 27% 4 5% (mean k SEM, n = 34), 150% k 22% (n = 40, P < .001 v rscu-PA), and 290% ? 41% per mg/kg (n = 37, P < .001 v rscu-PA and P = ,003 v K12GOS32), respectively. Maximal rates were obtained at dose of 0.77 ? 0. IO, 0.13 -t 0.02, and 0.066 mg/kg, respectively.
The specific thrombolytic activities of rscu-PA, K12GoS32, and K12G2S32 were determined by plotting percent lysis versus level of steady-state plasma u-PA-related antigen (pg/mL). The dose-response data, summarized in Table 4 , were fitted with the exponentially transformed sigmoidal function (Fig  3B) , yielding corresponding values for c' , z', and b' as illustrated in Table 5 . With K12GOS32, the maximal rate of lysis was ninefold higher than with rscu-PA (z' = 310% f 49%/ pg/mL and 36% f 5%/pg/mL, respectively; P < .OOl) and occurred at an 1 1 -fold lower plasma antigen level than with rscu-PA (b' = 0.060 +-0.00 I pg/mL and 0.63 f 0.12 pg/mL, For The plasma clearance (CI,) was calculated as the ratio of the infusion rate (pglmin) and the steady-state plasma concentration of antigen (pg/mL) at the end of the infusion, assuming an average body weight of 100 g.
respectively; P < .001). The maximal rate of thrombolysis with K12GZS32 (z' = 140 f 7) was twofold lower than that of K12GOS32 (P < .001), but still fourfold higher than that of rscu-PA (P < .001). Maximal rates of lysis with mu-PA,
K12GoS32
, and K12G2S32 were obtained at steady-state plasma u-PA antigen levels of 0.63 f 0.12, 0.060 * 0.01, and 0.17 f 0.04 pg/mL, respectively. However, when steady-state plasma levels of K12GOS32 and K12G2S32 were expressed in pg/mL fibrin D-dimer-binding protein, the values for b' were 0.09 f 0.01 and 0.12 * 0.01 pg/mL, respectively.
DISCUSSION
K12GOS32 is a 57,000 molecular weight single-chain chimeric PA consisting of a 25,000 molecular weight Fv fragment derived from the fibrin fragment D-dimer-specific antibody MA-15C5 fused to a 33,000 molecular weight derivative of rscu-PA, comprising amino acids Ala'32 through Leu4" in which the thrombin cleavage site is removed by substitution of PheL5' with Asp.I2 K12GOS32 was previously found to have a 13-fold higher fibrinolytic potency in an in vitro plasma clot lysis system than the unconjugated rscu-PA moiety, suggesting that the single-chain Fv fragment efficiently targets the PA to the plasma clot surface. K12G2S32 is a derivative of K12GoS32 in which the Asn-linked glycosylation site in the Fv moiety of K12GOS32 was removed by substitution of AsnS8 with Glu. The specific fibrinolytic activity and the specific plasma clot lysis activities in an in vitro clot lysis system of both single-chain and two-chain K12G2S32 were found to be comparable to those of their K12GOS32 counterpart. However, following bolus injection in hamsters, K12G2S32 was cleared from the circulation at a fourfold to fivefold slower rate than rscu-PA and K12GOS32, whereas in rabbits K12G2S32 had a 10-fold slower clearance than rscu-PA and K12GOS32. Still K12G2S32 was cleared threefold to fivefold faster than rscu-PA-32k/MA-15C5, a recombinant chimera consisting of scu-PA-32k fused to intact humanized MA-1 5C5.I'
The thrombolytic potencies (W lysis per mg u-PA equivalent administered per kg body weight) and the specific thrombolytic activities (% lysis per pg/mL steady-state u-PArelated antigen level in plasma) of rscu-PA, K12GOS32, and K12G2S32 were determined in hamsters with an experimental pulmonary embolus consisting of a human plasma clot. The maximal rate of lysis with KIZGOS32 was obtained at a sixfold lower dose and at a 10-fold lower steady-state plasma level than with rscu-PA, indicating that the increased thrombolytic potency of K12GOS32 is the result of fibrin-targeting of the chimera to the surface of the plasma clot via the Fv fragment. The maximal rate of lysis with K12G2S3z was obtained at a twofold lower dose, but at a threefold higher steady plasma u-PA antigen level than with K12GOS32, which is in agreement with the fourfold slower clearance and with the twofold lower specific thrombolytic activity of K12G2S32 than those of KIZGOS32. However, when the specific thrombolytic activities were expressed on the basis of the steady-state plasma levels of D-dimer-binding protein instead of on the basis of steadystate u-PA plasma levels, the values for K12GOS32 and K12G2S32 were similar. These findings can be explained by a twofold to threefold reduced fibrin-targeting capacity of the deglycosylated Fv fragment. With rscu-PA-32k/MA-15C5, the maximal rate of lysis in the hamster pulmonary embolism model was obtained with a fivefold lower dose than with that of K12G2S32 , l o whereas the clearance of rscu-PA-32k/MA-15C5 was fivefold slower than that of K12G2S32. In aggregate, these findings indicate that the in vivo fibrin-targeting capacity of the Fv fragment derived from MA-1 5C5 fused to scu-PA is similar to that of the intact antibody fused to scu-PA.
Chimeric molecules such as K12GZS32 are designed for potential use as thrombolytic agents. A 10-fold increase of the thrombolytic potency of K12G2S32 as compared with that of rscu-PA, might result in the reduction of the therapeutical dose from 100 to 10 mg, a significant but possibly submaximal improvement. Enhanced targeting ofthe PA to the thrombus For personal use only. on October 25, 2017. by guest www.bloodjournal.org From The individual dose-response data of lysis versus dose or lysis versus steady-state antigen level were fitted with an exponentially transformed sigmoidal function y = (lOOc)/(l + e-sle"-eDI). The mean ? SEM of the parameters b, c, and z, respectively, b, c' and z' were determined.
Abbreviations: z, i. maximal rate of lysis expressed as percent lysis per mg/kg dose (z), or percent lysis per pg/mL steady-state plasma antigen (2') . The values of z and z' were calculated as (ac/4). eb and (ac/4) .eb', respectively. b, b, Dose expressed in mg/kg (b), or antigen level expressed in pg/mL plasma (b), at which the rate of clot lysis is maximal. c, c', maximal rate of lysis achieved, expressed in percent. might further increase its thrombolytic potency. Alternative fibrin-specific monoclonal antibodies, including 59D8, which is directed against an epitope in the aminoterminal region in the /3-chain of fibrin: and 12B3, which is directed against an epitope in a 27-amino acid region spanning the carboxyterminal end of fragment E and the aminoterminal end of fragment D in the a-chain of fibrin,36 were found to have targeting capacities comparable to that of MA-1 5C59,36 (unpublished data) both in a hamster pulmonary embolism thrombosis model and in a rabbit jugular vein thrombosis model. Alternatively, reduction of the clearance rate might further increase the thrombolytic potency of the chimera. However, elucidation of the mechanisms of clearance of such single-chain constructs will require detailed structural investigation of the surfaces of both the Fv moiety and of the scu-PA moiety. Thus, although the thrombolytic potency of K12G2S32 may have to be further improved, K12G2S32 might have significant advantages over rscu-PA-32kIMA-15C5 for clinical use. The molecular weight of K12G2S32 is threefold lower than that of rscu-PA-32kIMA-I5C5. The lower molecular weight of K,2G2S32 might allow a better diffusion of the molecule into a thrombus, and the lack of an Fc domain might reduce specific binding to platelets and monocytes which contain Fc receptors at their surface. Moreover, the absence of constant domains in the single-chain constructs might reduce their immunogenicity.
Although the present study does not provide avenues to further improve the thrombolytic potency of single-chain chimeric PA, the demonstration that a single-chain antibody fragment can efficiently target PA to the thrombus provides a rational basis for the further investigation of this approach.
